BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 20950609)

  • 1. Overexpression of wild-type c-RET and zero prevalence of RET/PTC rearrangements are associated with papillary thyroid cancer (PTC) in Kuwait.
    El-Abdallah AA; Junaid TA
    Exp Mol Pathol; 2011 Feb; 90(1):61-5. PubMed ID: 20950609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RET/PTC Rearrangements Are Associated with Elevated Postoperative TSH Levels and Multifocal Lesions in Papillary Thyroid Cancer without Concomitant Thyroid Benign Disease.
    Su X; He C; Ma J; Tang T; Zhang X; Ye Z; Long Y; Shao Q; Shao J; Yang A
    PLoS One; 2016; 11(11):e0165596. PubMed ID: 27802347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [
    Zhang X; Su X; Chen WC; Li Y; Yang ZY; Deng WZ; Deng TC; Yang AK
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jun; 52(6):435-439. PubMed ID: 28635216
    [No Abstract]   [Full Text] [Related]  

  • 4. Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas.
    Nikiforova MN; Caudill CM; Biddinger P; Nikiforov YE
    Int J Surg Pathol; 2002 Jan; 10(1):15-22. PubMed ID: 11927965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of ret/PTC-1 rearrangements in neoplastic thyroid tissue using TaqMan RT-PCR.
    Sheils OM; O'Leary JJ; Sweeney EC
    J Pathol; 2000 Sep; 192(1):32-6. PubMed ID: 10951397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RET/PTC fusion gene rearrangements in Japanese thyroid carcinomas.
    Nibu K; Otsuki N; Nakao K; Sugasawa M; Rothstein JL
    Eur Arch Otorhinolaryngol; 2005 May; 262(5):368-73. PubMed ID: 15368067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application.
    Guerra A; Sapio MR; Marotta V; Campanile E; Moretti MI; Deandrea M; Motta M; Limone PP; Fenzi G; Rossi G; Vitale M
    Endocr J; 2011; 58(1):31-8. PubMed ID: 21173509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements.
    Mechler C; Bounacer A; Suarez H; Saint Frison M; Magois C; Aillet G; Gaulier A
    Br J Cancer; 2001 Dec; 85(12):1831-7. PubMed ID: 11747322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
    Guerra A; Zeppa P; Bifulco M; Vitale M
    Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expressions of wildtype-RET and RET/PTC rearrangements in sporadic adult papillary thyroid carcinoma and their clinicopathologic correlation].
    Zhu XL; Zhou XY; Zhang TM; Zhu XZ
    Zhonghua Bing Li Xue Za Zhi; 2006 Feb; 35(2):87-91. PubMed ID: 16630482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.
    Joung JY; Kim TH; Jeong DJ; Park SM; Cho YY; Jang HW; Jung YY; Oh YL; Yim HS; Kim YL; Chung JH; Ki CS; Kim SW
    Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma.
    Rhoden KJ; Unger K; Salvatore G; Yilmaz Y; Vovk V; Chiappetta G; Qumsiyeh MB; Rothstein JL; Fusco A; Santoro M; Zitzelsberger H; Tallini G
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2414-23. PubMed ID: 16595592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Break-apart interphase fluorescence in situ hybridization assay in papillary thyroid carcinoma: on the road to optimizing the cut-off level for RET/PTC rearrangements.
    Colato C; Vicentini C; Cantara S; Pedron S; Brazzarola P; Marchetti I; Di Coscio G; Chilosi M; Brunelli M; Pacini F; Ferdeghini M
    Eur J Endocrinol; 2015 May; 172(5):571-82. PubMed ID: 25698220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence of c-RET expression in papillary thyroid carcinomas from the Korean population.
    Lee S; Hong SW; Moon WC; Oh MR; Lee JK; Ahn CW; Cha BS; Kim KR; Lee HC; Lim SK
    Thyroid; 2005 Mar; 15(3):259-66. PubMed ID: 15785245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of PAX8/PPARG and RET/PTC rearrangements is feasible in routine air-dried fine needle aspiration smears.
    Ferraz C; Rehfeld C; Krogdahl A; Precht Jensen EM; Bösenberg E; Narz F; Hegedüs L; Paschke R; Eszlinger M
    Thyroid; 2012 Oct; 22(10):1025-30. PubMed ID: 23025542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - A molecular and clinical analysis.
    Musholt TJ; Staubitz JI; Antonio Cámara RJ; Musholt PB; Humberg D; Springer E; Schad A
    Eur J Surg Oncol; 2019 Jun; 45(6):1018-1024. PubMed ID: 30472213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint.
    Marotta V; Guerra A; Sapio MR; Vitale M
    Eur J Endocrinol; 2011 Oct; 165(4):499-507. PubMed ID: 21750045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing RET/PTC in thyroid nodule fine-needle aspirates: the FISH point of view.
    Caria P; Dettori T; Frau DV; Borghero A; Cappai A; Riola A; Lai ML; Boi F; Calò P; Nicolosi A; Mariotti S; Vanni R
    Endocr Relat Cancer; 2013 Aug; 20(4):527-36. PubMed ID: 23722226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
    Vasil'ev EV; Rumiantsev PO; Saenko VA; Il'in AA; Poliakova EIu; Nemtsova MV; Zaletaev DV
    Mol Biol (Mosk); 2004; 38(4):642-53. PubMed ID: 15456136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
    Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.